PDS Biotechnology (PDSB) Non-Current Debt (2014 - 2025)
PDS Biotechnology's (PDSB) quarterly Non-Current Debt came in at $11.7 million in Q4 2025, up 27.47% YoY from $9.2 million in Q4 2024, and down 1.31% on a QoQ basis from $11.9 million in Q3 2025.
PDS Biotechnology (PDSB) Non-Current Debt (2014 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 8 years of Non-Current Debt data on file, last reported at $11.7 million in Q4 2025.
- Quarterly Non-Current Debt rose 27.47% year-over-year to $11.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.7 million (up 27.47% YoY) and the FY2025 annual result came in at $11.7 million, up 27.47% from the prior year.
- Non-Current Debt slipped to $11.7 million in Q4 2025, from $11.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $23.4 million in Q3 2023 to a low of $6.4 million in Q1 2025.
- A 4-year average of $16.4 million and a median of $15.2 million in 2024 frame the typical range for Non-Current Debt.
- The widest YoY moves for Non-Current Debt: up 27.47% in 2025, down 61.85% in 2025.
- Tracing PDSB's Non-Current Debt over 4 years: stood at $23.0 million in 2022, then slipped by 15.27% to $19.5 million in 2023, then slumped by 52.81% to $9.2 million in 2024, then increased by 27.47% to $11.7 million in 2025.
- The last three Non-Current Debt figures came in at $11.7 million (Q4 2025), $11.9 million (Q3 2025), and $12.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.73 Mn |
| Sep 30, 2025 | 11.89 Mn |
| Jun 30, 2025 | 12.94 Mn |
| Mar 31, 2025 | 6.35 Mn |
| Dec 31, 2024 | 9.20 Mn |
| Sep 30, 2024 | 12.03 Mn |
| Jun 30, 2024 | 13.81 Mn |
| Mar 31, 2024 | 16.65 Mn |
| Dec 31, 2023 | 19.51 Mn |
| Sep 30, 2023 | 23.41 Mn |
| Jun 30, 2023 | 23.25 Mn |
| Mar 31, 2023 | 23.14 Mn |
| Dec 31, 2022 | 23.02 Mn |
| Sep 30, 2022 | 22.91 Mn |
| Dec 31, 2017 | 17.38 Mn |
| Sep 30, 2017 | 14.88 Mn |
| Jun 30, 2017 | 17.13 Mn |
| Mar 31, 2017 | 14.51 Mn |
| Dec 31, 2016 | 14.95 Mn |
| Sep 30, 2016 | 14.82 Mn |